桃红四物汤加减治疗中青年单纯舒张期高血压病（气滞血瘀型）的临床疗效观察

Clinical observation of modified Taohong Siwu Decoction for the treatment of isolated diastolic hypertension（qi stagnation and blood stasis type）in young and middle-aged people

关键词:  桃红四物汤加减  中青年  单纯舒张期高血压病  气滞血瘀

Key words:  modified Taohong Siwu Decoction  young and middle-aged people  isolated diastolic hypertension  qi stagnation and blood stasis type

摘要:

[目的] 观察桃红四物汤加减治疗中青年单纯舒张期高血压病（气滞血瘀型）的临床疗效。[方法] 纳入2022年9月—2025年11月就诊于鄂尔多斯市中医医院门诊及住院的气滞血瘀型中青年单纯舒张期高血压病患者，采用随机对照法，将入组患者随机分为对照组、治疗1组和治疗2组，每组37例。对照组给予苯磺酸氨氯地平片治疗，治疗1组给予桃红四物汤加减治疗，治疗2组在对照组的基础上联合桃红四物汤加减治疗，疗程均为5周。对治疗前后血压、心率、中医证候、血脂及不良反应进行评估分析。[结果] 治疗后3组患者治疗后的诊室收缩压（SBP）、舒张压（DBP）、中医证候积分及心率方面显著降低（P<0.05），治疗1、2组改善中医证候、降低心率、降压有效率方面显著优于对照组（P<0.05）；治疗1、2组显著降低总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C，P<0.05），升高高密度脂蛋白胆固醇（HDL-C，P<0.05），且在降低TC、TG、LDL-C，升高HDL-C方面较对照组有显著性差异（P<0.05）。[结论] 桃红四物汤加减单用或联合西药在治疗气滞血瘀型中青年单纯舒张期高血压病上具有明显的临床疗效，能降低患者的血压水平，改善患者的中医证候、血脂，降低患者心率；且在改善中医证候疗效、血脂与降低心率方面均优于单一西药治疗。此外，该治疗方案临床应用未见明显不良反应，可作为临床用药选择方案。

Abstract:

[Objective] To observe the clinical efficacy of modified Taohong Siwu Decoction in treating isolated diastolic hypertension（qi stagnation and blood stasis type） in young and middle-aged people. [Methods] Young and middle-aged people with isolated diastolic hypertension of qi stagnation and blood stasis type who visited the outpatient and inpatient departments of Ordos Hospital of Traditional Chinese Medicine from September 2022 to November 2025 were selected. A randomized controlled method was used to randomly divided the enrolled patients into the control group，treatment group 1，and treatment group 2，with 37 cases in each group. The control group was treated with amlodipine besylate tablets，the treatment group 1 was treated with modified Taohong Siwu Decoction，and the treatment group 2 was treated with combined modified Taohong Siwu Decoction on the basis of the control group.The treatment period for three groups was 5 weeks. The blood pressure，heart rate，traditional Chinese medicine syndrome，lipid profile，and adverse reactions before and after treatment were evaluated and analyzed. [Results] After treatment，the systolic blood pressure（SBP），diastolic blood pressure（DBP），Chinese medicine syndrome score，and heart rate of the three groups of patients were significantly lower（P<0.05），and the treatment group 1 and treatment group 2 were significantly better than the control group in improving traditional Chinese medicine syndrome，efficacy rate of blood pressure reduction andreducing heart rates（P<0.05）. The treatment group 2 was significantly better than the control group in the markedefficacy rate of blood pressure reduction（P<0.05）. Treatment groups 1 and 2 significantly reduced total cholesterol（TC），triglycerides（TG），and low-density lipoprotein cholesterol（LDL-C，P<0.05），increased high-density lipoprotein cholesterol（HDL-C，P<0.05），and had significant differences compared with the control group in reducing TC，TG，LDL-C，and increasing HDL-C（P<0.05）.[Conclusion] The modified Taohong Siwu Decoction，when used alone or in combination with conventional Western medicine，demonstrates significant clinical efficacy in the treatment of middle-aged and young people with isolated diastolic hypertension of qi stagnation and blood stasis type. It can effectively lower patients’ blood pressure levels，improve their traditional Chinese medicine（TCM） syndromes and blood lipid profiles，and reduce their heart rates. Moreover，it outperforms conventional Western medicine treatment in terms of improving the efficacy on TCM syndromes，enhancing blood lipid profiles，and lowering heart rates. Additionally，this treatment regimen exhibits good clinical safety with no obvious adverse reactions observed，making it a viable option for clinical medication selection.